摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-((tert-butoxycarbonyl)amino)butyl methanesulfonate | 98082-30-5

中文名称
——
中文别名
——
英文名称
3-((tert-butoxycarbonyl)amino)butyl methanesulfonate
英文别名
Tert-butyl N-[4-(methanesulfonyloxy)butan-2-yl]carbamate;3-[(2-methylpropan-2-yl)oxycarbonylamino]butyl methanesulfonate
3-((tert-butoxycarbonyl)amino)butyl methanesulfonate化学式
CAS
98082-30-5
化学式
C10H21NO5S
mdl
——
分子量
267.346
InChiKey
NNMCAJYXRIQQLW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    82.5-83 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
  • 沸点:
    418.0±28.0 °C(Predicted)
  • 密度:
    1.143±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    17
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    90.1
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-((tert-butoxycarbonyl)amino)butyl methanesulfonate 在 lithium aluminium tetrahydride 、 potassium carbonate三乙胺 作用下, 以 乙醚二氯甲烷二甲基亚砜N,N-二甲基甲酰胺 为溶剂, 反应 29.83h, 生成 C27H38N4O8S
    参考文献:
    名称:
    The Use of Novel C-Methylated Spermidine Derivatives To Investigate the Regulation of Polyamine Metabolism
    摘要:
    The polyamines are organic polycations present at millimolar concentrations in eukaryotic cells where they participate in the regulation of vital cellular functions including proliferation and differentiation. Biological evaluation of rationally designed polyamine analogs is one of the cornerstones of polyamine research. Here we have synthesized and characterized novel C-methylated spermidine analogs, that is, 2-methylspermidine, 3-methylspermidine, and 8-methylspermidine. 3-Methylspermidine was found to be metabolically stable in DU145 cells, while 8-methylspermidine was a substrate for spermidine/spermine N(1)-acetyltransferase (SSAT) and 2-methylspermidine was a substrate for both SSAT and acetylpolyamine oxidase. All the analogs induced the splicing of the productive mRNA splice variant of SSAT, overcame growth arrest induced by 72-h treatment with ornithine decarboxylase (ODC), inhibitor alpha-difluoromethylornithine, and were transported via the poly amine transporter. Surprisingly, 2-methylspermidine was a weak downregulator of ODC activity in DU145 cells. Our data demonstrates that it is possible to radically alter the biochemical properties of a polyamine analog by changing the position of the methyl group.
    DOI:
    10.1021/jm200293r
  • 作为产物:
    参考文献:
    名称:
    [EN] BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6
    [FR] INHIBITEURS DE BCL6 DÉRIVÉS DE BENZIMIDAZOLONE
    摘要:
    本发明涉及作为BCL6(B细胞淋巴瘤6)活性抑制剂的Formula I化合物:其中X1、X2、R1、R2和R3如本文所定义。本发明还涉及制备这些化合物的方法,包括含有它们的药物组合物,以及它们在治疗增生性疾病(如癌症)以及BCL6活性有所涉及的其他疾病或病况中的用途。
    公开号:
    WO2018215801A1
点击查看最新优质反应信息

文献信息

  • MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO
    申请人:Dow AgroSciences LLC
    公开号:US20170210723A1
    公开(公告)日:2017-07-27
    This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, compositions containing such molecules, and processes of using such molecules and compositions against such pests. These molecules and compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).
    这份披露涉及具有对节肢动物门、软体动物门和线虫门害虫具有杀虫效用的分子领域,用于生产这种分子的过程,用于这种过程的中间体,含有这种分子的组合物,以及使用这种分子和组合物对抗这些害虫的过程。这些分子和组合物可以用作杀螨剂杀虫剂杀螨剂、杀软体动物剂和杀线虫剂。本文件披露了具有以下式(“式一”)的分子。
  • [EN] INHIBITORS OF BACTERIAL GLYCOSYL TRANSFERASES<br/>[FR] INHIBITEURS DE GLYCOSYL TRANSFÉRASES BACTÉRIENNES
    申请人:HARVARD COLLEGE
    公开号:WO2016191658A1
    公开(公告)日:2016-12-01
    Described herein are compounds of Formula (I'), Formula (IA), Formulae (I)-(VII), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrug sthereof. The invention also provides pharmaceutical compositions of the compounds for human and veterinary use. Compounds of the present invention are useful for inhibiting bacterial growth and therefore are useful in treating and/or preventing bacterial infections. Methods of using the compounds for treating and/or preventing a bacterial infection in a subject are also described.
    本文描述了式(I')、式(IA)、式(I)-(VII)的化合物,以及这些化合物的药用盐、溶剂合物、合物、多型体、共晶体、互变异构体、立体异构体、同位素标记衍生物和前药。本发明还提供了这些化合物的用于人类和兽医用途的药物组合物。本发明的化合物对抑制细菌生长有用,因此在治疗和/或预防细菌感染方面具有用途。还描述了使用这些化合物治疗和/或预防受试者细菌感染的方法。
  • [EN] INHIBITORS OF LEUCINE RICH REPEAT KINASE 2<br/>[FR] INHIBITEURS DE LA KINASE 2 À RÉPÉTITION RICHE EN LEUCINE
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2019012093A1
    公开(公告)日:2019-01-17
    The present invention relates to novel compounds that inhibit LRRK2 kinase activity, to processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
    本发明涉及抑制LRRK2激酶活性的新化合物,以及它们的制备方法、含有它们的组合物,以及它们在治疗或预防与LRRK2激酶活性相关或以其为特征的疾病中的应用,例如帕森病、阿尔茨海默病和肌萎缩侧索硬化症(ALS)。
  • Metallo-beta-lactamase inhibitors
    申请人:Merck Sharp & Dohme Corp.
    公开号:US10221163B2
    公开(公告)日:2019-03-05
    The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
    本发明涉及式 I 的属-β-内酰胺酶抑制剂化合物:及其药学上可接受的盐,其中 Z、RA、X1、X2 和 R1 如本文所定义。本发明还涉及组合物,其包含本发明的属-β-内酰胺酶抑制剂化合物或其药学上可接受的盐,以及药学上可接受的载体,可选择与β-内酰胺抗生素和/或β-内酰胺酶抑制剂结合使用。本发明进一步涉及治疗细菌感染的方法,包括向患者施用治疗有效量的本发明化合物,与治疗有效量的一种或多种β-内酰胺类抗生素联合使用,也可选择与一种或多种β-内酰胺酶抑制剂化合物联合使用。本发明的化合物在本文所述的克服抗生素耐药性的方法中是有用的。
  • [EN] MACROCYCLIC KINASE INHIBITOR<br/>[FR] INHIBITEUR DE KINASE MACROCYCLIQUE<br/>[ZH] 一种大环类激酶抑制剂
    申请人:HITGEN INC
    公开号:WO2019201282A1
    公开(公告)日:2019-10-24
    本发明公开了一种大环类激酶抑制剂,该化合物、或其立体异构体、或其药学上可接受的盐如式I所示。实验表明,本发明公开的式I所示的新化合物,表现出了良好的TRK抑制活性,对TRKA突变细胞生长具有显著抑制作用,并且展现出良好的体内肿瘤生长抑制作用,为临床治疗与TRK活性异常相关的疾病提供了一种新的选择。
查看更多